The chronic gout market is expected to maintain a stable growth over the forecast period (2025–2034). This growth is fueled by increasing prevalence due to aging populations and cardiometabolic ...

Individuals with gout are more likely than those without the disease to receive chronic opioid therapy, independent of other ...

XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat ...

Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Patients with gout in chronic kidney disease are undertreated, and health care providers need to ...

Am J Health Syst Pharm. 2011;68(5):389-398. Gout flares typically begin abruptly, with red, hot, or tender joints. Individuals may also be febrile during gouty attacks. Attacks may be polyarticular ...

As an alternative to a conventional treatment for gout that some patients may not respond to, patients with severe, chronic gout who received the medication pegloticase for six months had greater ...

Patients with gout are more likely than those without to initiate chronic opioid use. Patients with gout are more likely than those without to initiate chronic opioid use, according to study results ...

What are the most current recommendations for treatment of acute and chronic gout? Please also include the latest preventive and dietary recommendations. The advent of cyclooxygenase-2 ...

An immunotherapy treatment for gout is being tested for safety and efficacy. A diagnosis of incident or new chronic pain may be twice as likely in patients with vs without gout. A diagnosis of ...

BLOOM (TAMPA) – Nephrologist Jason B. Rothschild, MD, recently joined Gayle Guyardo, the host of the globally syndicated health and wellness show Bloom, to discuss the often-overlooked connection ...

CKD stage 2 through stage 5 with hyperuricemia and a history of acute gout activity is, by itself, an indication to initiate ULT. 5 The target serum uric acid should <6 mg/dL. To achieve symptomatic ...

(MENAFN- GlobeNewsWire - Nasdaq) The chronic gout market is expected to maintain a stable growth over the forecast period (2025–2034). This growth is fueled by increasing prevalence due to aging ...